Drug patents are being abused, driving unsustainable health care costs. Until now, transparent patent and market information has not been available to the public in one simple and easy resource.
10 Drugs
Top Selling
in America in 2021
700+ Patents
On these 10 drugs
restrict competition
66%
Patents filed after
FDA approval
| Drug | Total Patent Applications |
# Patents Granted |
% Filed after FDA Approval |
Duration of Patent Protection |
Patent Applications in U.S. vs EU |
Patents Granted in U.S. vs EU |
Total Price Increase Since Launch (WAC) |
Total 5yr Price Increase (WAC, 2016-2021) |
5yr Price Increase vs Inflation, Multiple |
Medicare Avg. Annual Growth Rate in Spending per Dosage Unit (2017-2021) |
Overall U.S. Spend 2021 Rank |
Medicare Top 12 Total Spending Rank (2021) |
Medicare + Medicaid Top 12 Total Spending Rank (2021) |
Medicare Spending per Beneficiary (2021) |
Total U.S. Revenues Since Launch ($ billions) |
% of Co.'s 2021 U.S. Pharma Revenue |
First U.S./FDA Approval Date |
First Europe/EMA Approval Date |
First Generic/ Biosimilar on the U.S. Market |
First Generic/ Biosimilar on the EU market |
Drug (Nonproprietary Name) |
Company | Primary Condition Treated |
Drug Type |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Humira | 311 | 165 | 92% | 43.3 | 3.0 | 6.4 | 506% | 60% | 4.6x | 7.8% | 1 | 4 | 5 | $56,752 | $128.6 | 40% | 12-2002 | 9-2003 | 1-2023 | 10-2018 | adalimumab | AbbVie | Arthritis | Biologic |
| Keytruda | 180 | 78 | 62% | 37.3 | 1.3 | 1.7 | 19% | 14% | 1.1x | 0.2% | 2 | 7 | 8 | $63,131 | $32.1 | 48% | 9-2014 | 7-2015 | pembrolizumab | Merck | Cancer | Biologic | ||
| Revlimid | 206 | 117 | 74% | 42.9 | 2.6 | 4.0 | 287% | 56% | 4.4x | 7.6% | 3 | 2 | 2 | $129,242 | $61.4 | 30% | 12-2005 | 6-2007 | 3-2022 | 2-2022 | lenalidomide | Bristol-Myers Squibb (Celgene) | Multiple Myeloma | Small Molecule |
| Biktarvy | 73 | 44 | 12% | 49 | 1.9 | 2.3 | 21% | 15% | 1.2x | 6.1% | 4 | - | 7 | $33,147 | $20.2 | 37% | 2-2018 | 6-2018 | bictegravir | Gilead | HIV | Small Molecule | ||
| Eliquis | 43 | 22 | 37% | 34.1 | 2.4 | 2.4 | 112% | 50% | 3.9x | 7.3% | 5 | 1 | 1 | $4,024 | $29.0 | 22% | 12-2012 | 5-2011 | 5-2022 | apixaban | Bristol-Myers Squibb (Celgene) | Stroke/ Embolism | Small Molecule | |
| Stelara | 76 | 39 | 75% | 39.5 | 1.9 | 2.8 | 171% | 44% | 3.4x | 6.5% | 6 | - | - | $97,022 | $30.4 | 21% | 9-2009 | 1-2009 | ustekinumab | Johnson & Johnson | Psoriasis | Biologic | ||
| Eylea | 134 | 91 | 66% | 44.3 | 3.6 | 7.7 | - | - | 0.0x | -1.4% | 7 | 9 | 10 | $11,030 | $34.7 | 48% | 11-2011 | 11-2012 | aflibercept | Regeneron/ Bayer | Macular Degeneration | Biologic | ||
| Trulicity | 57 | 15 | 86% | 35.8 | 1.2 | 1.5 | 82% | 47% | 3.7x | 7% | 8 | 8 | 6 | $7,083 | $18.3 | 29% | 9-2014 | 11-2014 | dulaglutide | Eli Lilly | Diabetes | Biologic | ||
| Enbrel | 154 | 74 | 90% | 49.7 | 1.8 | 4.1 | 617% | 54% | 4.2x | 8.3% | 9 | - | - | $50,159 | $75.9 | 24% | 11-1998 | 2-2000 | 2-2016 | etanercept | Amgen | Arthritis | Biologic | |
| Imbruvica | 195 | 96 | 62% | 29.2 | 4.1 | 8.0 | 94% | 57% | 4.4x | 35.7% | 10 | 11 | 11 | $120,958 | $21.5 | 10% | 11-2013 | 10-2014 | ibrutinib | AbbVie / Johnson & Johnson | Cancer | Small Molecule | ||
| Average | 142.9 | 74.1 | 66% | 40.5 | 2.4x | 4.1 | 212% | 44% | 3.1x | 9% | $57,255 | $45.2 | 31% |
Numbers in pink font indicate above the average for the 10 drugs
Powerful search and compare functions to deliver detailed data.
Verifying and strengthening reporting with a data-driven foundation.
Quickly and easily accessing the data needed to make informed policy decisions.
Detailed information about the drugs you pay for everyday.
We deserve transparency and access to the information about the drug patents impacting Americans and their healthcare. Lack of critical data on patents prevents lawmakers from making informed decisions which have the potential to reduce prescription drug costs.
Learn how to quickly and easily access the data you deserve to know.
Access The Full Patent DatabaseRead our investigations about everyday drugs that are overpatented and overpriced. Click each one to read more:
Partner with us now to build
a more just and equitable
medicine system for all.